{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T00:15:08Z","timestamp":1794442508227,"version":"4.9.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019717","name":"AstraZeneca Espa\u00f1a","doi-asserted-by":"publisher","award":["ESR-17-13224"],"award-info":[{"award-number":["ESR-17-13224"]}],"id":[{"id":"10.13039\/100019717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.lungcan.2025.108553","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T19:07:19Z","timestamp":1745262439000},"page":"108553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial"],"prefix":"10.1016","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7146-9071","authenticated-orcid":false,"given":"Matthias","family":"Guckenberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5900-9040","authenticated-orcid":false,"given":"Isabelle","family":"Opitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Dellaporta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5778-5270","authenticated-orcid":false,"given":"Alessandra","family":"Curioni-Fontecedro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3295-6619","authenticated-orcid":false,"given":"Thomas","family":"Frauenfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4724-1197","authenticated-orcid":false,"given":"Karin","family":"Ribi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8987-5732","authenticated-orcid":false,"given":"Ferdinando","family":"Cerciello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0434-3436","authenticated-orcid":false,"given":"Ivana","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3521-2535","authenticated-orcid":false,"given":"Lizza","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2167-8358","authenticated-orcid":false,"given":"Miriam","family":"Dorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2556-8412","authenticated-orcid":false,"given":"Ana","family":"Callejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Addeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6105-182X","authenticated-orcid":false,"given":"Anne-Marie C.","family":"Dingemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8741-6038","authenticated-orcid":false,"given":"Giulia","family":"Pasello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Provencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"de Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3083-0721","authenticated-orcid":false,"given":"Nuria","family":"Mederos-Alfonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5432-2385","authenticated-orcid":false,"given":"Heidi","family":"Roschitzki-Voser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Ruepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5704-7721","authenticated-orcid":false,"given":"Martina","family":"Haberecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5572-7894","authenticated-orcid":false,"given":"Roswitha","family":"Kammler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4367-4497","authenticated-orcid":false,"given":"Urania","family":"Dafni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4815-8870","authenticated-orcid":false,"given":"Rolf","family":"Stahel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2025.108553_b0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108553_b0010","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jtho.2019.07.025","article-title":"Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report","volume":"14","author":"Dingemans","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108553_b0015","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108553_b0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative Radiotherapy for Limited Metastatic Non\u2013Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108553_b0025","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer","volume":"115","author":"Wang","year":"2022","journal-title":"JNCI: J. Natl. Cancer Inst."},{"issue":"18","key":"10.1016\/j.lungcan.2025.108553_b0030","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study","volume":"37","author":"Gomez","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"10422","key":"10.1016\/j.lungcan.2025.108553_b0035","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet (London, England)"},{"issue":"10185","key":"10.1016\/j.lungcan.2025.108553_b0040","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"25","key":"10.1016\/j.lungcan.2025.108553_b0045","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial","volume":"38","author":"Palma","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108553_b0050","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/JTO.0b013e318262caf6","article-title":"Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450)","volume":"7","author":"De Ruysscher","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108553_b0055","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","article-title":"Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non\u2013Small Cell Lung Cancer: A Phase 2 Trial","volume":"5","author":"Bauml","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2025.108553_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101892","article-title":"Evolution of treatment strategies for oligometastatic NSCLC patients - A systematic review of the literature","volume":"80","author":"Schanne","year":"2019","journal-title":"Cancer Treat. Rev."},{"issue":"24","key":"10.1016\/j.lungcan.2025.108553_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246374","article-title":"Patient Selection for Local Aggressive Treatment in Oligometastatic Non-Small Cell Lung Cancer","volume":"13","author":"Werner","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.lungcan.2025.108553_b0070","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ctrv.2016.11.013","article-title":"Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review","volume":"53","author":"Kroeze","year":"2017","journal-title":"Cancer Treat. Rev."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108553_b0075","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC\u2013ESTRO OligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol."},{"issue":"7547","key":"10.1016\/j.lungcan.2025.108553_b0080","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.lungcan.2025.108553_b0085","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108553_b0090","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.prro.2023.04.004","article-title":"Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO\/ESTRO Clinical Practice Guideline","volume":"13","author":"Iyengar","year":"2023","journal-title":"Pract. Radiat. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108553_b0095","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer (Oxford England : 1990)"},{"key":"10.1016\/j.lungcan.2025.108553_b0100","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S0959-8049(05)80262-X","article-title":"Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS)","volume":"29","author":"Hollen","year":"1993","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108553_b0105","first-page":"213","article-title":"Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS)","volume":"2","author":"Hollen","year":"1994","journal-title":"Support. Care Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2025.108553_b0110","first-page":"140","article-title":"Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS)","volume":"7","author":"Hollen","year":"1999","journal-title":"Support. Care Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108553_b0115","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108553_b0120","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/j.cllc.2019.06.024","article-title":"Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT","volume":"20","author":"H\u00f6rner-Rieber","year":"2019","journal-title":"Clin. Lung Cancer"},{"issue":"190","key":"10.1016\/j.lungcan.2025.108553_b0125","article-title":"Treatment outcome of patients with synchronous oligometastatic non-small cell lung cancer in the immunotherapy era: Analysis of a real-life intention-to-treat population","volume":"2023","author":"Jongbloed","year":"1990","journal-title":"Eur. J. Cancer (Oxford England: 1990)"},{"issue":"5","key":"10.1016\/j.lungcan.2025.108553_b0130","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jamaoncol.2024.0057","article-title":"Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis","volume":"10","author":"Sorin","year":"2024","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108553_b0135","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13014-020-01730-0","article-title":"Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the 'TOaSTT' database","volume":"16","author":"Kroeze","year":"2021","journal-title":"Radiat. Oncol. (Lond., England)"},{"issue":"6","key":"10.1016\/j.lungcan.2025.108553_b0140","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/ejcts\/ezz384","article-title":"Prognostic factors of oligometastatic non-small-cell lung cancer following radical therapy: a multicentre analysis","volume":"57","author":"Opitz","year":"2020","journal-title":"Eur. J. Cardiothorac. Surg."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108553_b0145","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non\u2013Small-Cell Lung Cancer: The Phase III POSEIDON Study","volume":"41","author":"Johnson","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108553_b0150","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008189","article-title":"Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial","volume":"12","author":"Carbone","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108553_b0155","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jtho.2021.08.019","article-title":"A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study","volume":"17","author":"Bestvina","year":"2022","journal-title":"J. Thorac. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225004453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225004453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T20:21:00Z","timestamp":1753993260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225004453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":31,"alternative-id":["S0169500225004453"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108553","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108553","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108553"}}